Maxis AI Information

Maxis AI (formerly MaxisIT), headquartered in Edison, New Jersey, has introduced the first AI Workforce for Clinical Trials - a supervised execution layer built for regulated clinical environments. Clinical development does not lack visibility. It lacks scalable execution capacity alongside reliability, reproducibility of outcomes, and risk resolution. Maxis AI enables sponsors and CROs to execute defined clinical workflows through governed AI agents operating under expert supervision. Built on experience from more than 3,300 clinical trials, the Maxis AI platform performs structured operational work across study startup, enrollment support, clinical data management, statistical programming, medical writing, and governed risk oversight & resolution. The Maxis AI Workforce operates within existing clinical systems and follows controlled permissions, validation checkpoints, and clear accountability structures. By combining intelligent workflow orchestration with human-in-the-loop validation, audit traceability, and service-level accountability, Maxis AI enables higher operational throughput without proportional headcount growth. By changing how execution capacity is delivered, Maxis AI helps clinical development organizations align cost with output rather than headcount and improve predictability across portfolios while maintaining regulatory confidence. Our mission is to evolve the new operating model of clinical development, so innovative therapies reach patients faster with discipline, governance, and measurable impact. Designed to Think. Built to Act.